Matthieu Sarabi

2.0k total citations
27 papers, 407 citations indexed

About

Matthieu Sarabi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Matthieu Sarabi has authored 27 papers receiving a total of 407 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 5 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Matthieu Sarabi's work include Cancer Immunotherapy and Biomarkers (7 papers), Pancreatic and Hepatic Oncology Research (7 papers) and Renal cell carcinoma treatment (5 papers). Matthieu Sarabi is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Pancreatic and Hepatic Oncology Research (7 papers) and Renal cell carcinoma treatment (5 papers). Matthieu Sarabi collaborates with scholars based in France, Sweden and Netherlands. Matthieu Sarabi's co-authors include Christophe Caux, Pacôme Lecot, Nathalie Bendriss‐Vermare, Julie Mussard, Marie‐Cécile Michallet, Leo Koenderman, Lars Lind, Christelle de la Fouchardière, Françoise Desseigne and Thomas Kahan and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Hepatology and British Journal of Cancer.

In The Last Decade

Matthieu Sarabi

24 papers receiving 401 citations

Peers

Matthieu Sarabi

ONCOL

IMMUN

CCM

PRM

SURGE

Anat Shriki Israel

Shengjue Xiao China

Takeshi Hagino Japan

Colleen Gilbert United States

Süleyman Hilmi İpekçi Türkiye

Marloes G. J. van Dongen Netherlands

Gadi Shlomai Israel

Lijiang Tang China

Noemi Michetti Italy

Anat Shriki Israel

Matthieu Sarabi

84 ×0.5

ONCOL

75 ×0.7

IMMUN

28 ×0.4

CCM

51 ×0.8

PRM

67 ×1.0

SURGE

Citations per year, relative to Matthieu Sarabi Matthieu Sarabi (= 1×) peers Anat Shriki

Countries citing papers authored by Matthieu Sarabi

Since Specialization

Citations

This map shows the geographic impact of Matthieu Sarabi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthieu Sarabi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthieu Sarabi more than expected).

Fields of papers citing papers by Matthieu Sarabi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthieu Sarabi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthieu Sarabi. The network helps show where Matthieu Sarabi may publish in the future.

Co-authorship network of co-authors of Matthieu Sarabi

This figure shows the co-authorship network connecting the top 25 collaborators of Matthieu Sarabi. A scholar is included among the top collaborators of Matthieu Sarabi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthieu Sarabi. Matthieu Sarabi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fouchardière, Christelle de la, Pia Gamradt, Sylvie Chabaud, et al.. (2022). A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC: The Stromal Protein βig-h3. Journal of Personalized Medicine. 12(4). 623–623. 2 indexed citations

Hautefeuille, Vincent, Édouard Auclin, Astrid Lièvre, et al.. (2022). Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study. British Journal of Cancer. 126(10). 1394–1400. 5 indexed citations

Roth, Gaël S., et al.. (2022). Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine ?. European Journal of Cancer. 179. 1–14. 16 indexed citations

Coutzac, Clélia, Matthieu Sarabi, Françoise Desseigne, et al.. (2021). Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report. Frontiers in Oncology. 11. 756365–756365. 2 indexed citations

Desseigne, Françoise, Valérie Bonadona, Sophie Dussart, et al.. (2021). Immune Checkpoint Inhibitor Sensitivity of DNA Repair Deficient Tumors. Immunotherapy. 13(14). 1205–1213.

Hautefeuille, Vincent, Édouard Auclin, Astrid Lièvre, et al.. (2020). PD-6 Gemcitabine + nab-paclitaxel or gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: A population-based, multicenter AGEO study. Annals of Oncology. 31. S213–S214. 1 indexed citations

Sarabi, Matthieu, et al.. (2019). Use's assessment of geriatric variables in the older patient with cancer's multidisciplinary team meeting. Journal of Geriatric Oncology. 11(3). 536–539. 3 indexed citations

Lardy-Cléaud, Audrey, et al.. (2019). FOLFIRINOX in Patients With Peritoneal Carcinomatosis From Pancreatic Adenocarcinoma: A Retrospective Study. Current Oncology. 26(4). 466–472. 6 indexed citations

Lecot, Pacôme, Matthieu Sarabi, Julie Mussard, et al.. (2019). Neutrophil Heterogeneity in Cancer: From Biology to Therapies. Frontiers in Immunology. 10. 2155–2155. 117 indexed citations

10.

Fouchardière, Arnaud de la, Matthieu Sarabi, Françoise Desseigne, et al.. (2018). Primary Malignant Melanoma of the Esophagus, Treated with Immunotherapy: A Case Report. Immunotherapy. 10(10). 831–835. 12 indexed citations

11.

Cassier, Philippe A., Christelle de la Fouchardière, Pierre Guibert, et al.. (2017). Actionable molecular alterations in advanced biliary tract carcinomas: Preliminary data from the ProfiLER program (NCT01774409). Annals of Oncology. 28. v247–v247. 1 indexed citations

12.

Sarabi, Matthieu, et al.. (2017). Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma. Oncology Letters. 13(6). 4917–4924. 21 indexed citations

13.

Sarabi, Matthieu, et al.. (2016). Psychoactive drugs influence brain-derived neurotrophic factor and neurotrophin 4/5 levels in the serum of colorectal cancer patients. Biomedical Reports. 6(1). 89–94. 11 indexed citations

14.

Bourien, Héloïse, Astrid Lièvre, Marie Dupuy, et al.. (2016). Analysis of medical practices for French patients with BRAF mutant metastatic colorectal cancer.. Journal of Clinical Oncology. 34(15_suppl). e15070–e15070. 1 indexed citations

15.

Carrier, Paul, Jérémie Jacques, Marilyne Debette‐Gratien, et al.. (2014). L’ascite non liée à la cirrhose : physiopathologie, diagnostic et étiologies. La Revue de Médecine Interne. 35(6). 365–371. 17 indexed citations

16.

Eriksson, Mats, Kari Johansson, Matthieu Sarabi, & Lars Lind. (2007). Mental Stress Impairs Endothelial Vasodilatory Function by a Beta-Adrenergic Mechanism. Endothelium. 14(3). 151–156. 19 indexed citations

17.

Sarabi, Matthieu, et al.. (2003). Blood flow is an important determinant of forearm glucose uptake following a mixed meal. Acta Diabetologica. 40(3). 113–117. 9 indexed citations

18.

Holmlund, Anders, J. Hulthe, Jonas Millgård, et al.. (2002). Soluble intercellular adhesion molecule-1 is related to endothelial vasodilatory function in healthy individuals. Atherosclerosis. 165(2). 271–276. 39 indexed citations

19.

Sarabi, Matthieu. (2001). Endothelium-dependent vasodilation is related to the fatty acid composition of serum lipids in healthy subjects. Atherosclerosis. 156(2). 349–355. 60 indexed citations

20.

Sarabi, Matthieu, Jonas Millgård, Anders Hägg, et al.. (1999). Endothelin plays an important role in the endothelium-dependent vasodilatation in the human forearm. Scandinavian Journal of Clinical and Laboratory Investigation. 59(1). 17–22. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact